SHCM
ADMA icon

Sachem Head Capital Management’s ADMA Biologics ADMA Stock Holding History

Sachem Head Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,375,000
Closed -$207M – 20
2025
Q4 		$207M Buy
11,375,000
+2,415,000
+27% +$40.7M 4.86% 10
2025
Q3 		$131M Buy
+8,960,000
New +$154M 3.71% 12

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Sachem Head Capital Management's ADMA Position: Q1 2026 in Review

Sachem Head Capital Management sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 11,375,000 shares — an estimated $207M sold.

Sachem Head Capital Management first reported a position in ADMA in Q3 2025 and held it in 2 quarters. The position peaked at $207M in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Sachem Head Capital Management reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Sachem Head Capital Management sold 11,375,000 ADMA Biologics shares in Q1 2026, an estimated $207M.
  • Sachem Head Capital Management first reported a position in ADMA Biologics in Q3 2025 and held it in 2 quarters.
  • Sachem Head Capital Management's ADMA Biologics position peaked at $207M in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Sachem Head Capital Management's 13F filing for Q1 2026, filed 15 May 2026.